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p27Kip1 controls cell proliferation by binding to
and regulating the activity of cyclin-dependent
kinases (Cdks). Here we show that Cdk inhibi-
tion and p27 stability are regulated through
direct phosphorylation by tyrosine kinases. A
conserved tyrosine residue (Y88) in the Cdk-
binding domain of p27 can be phosphorylated
by the Src-family kinase Lyn and the oncogene
product BCR-ABL. Y88 phosphorylation does
not prevent p27 binding to cyclin A/Cdk2.
Instead, it causes phosphorylated Y88 and the
entire inhibitory 310-helix of p27 to be ejected
from the Cdk2 active site, thus restoring partial
Cdk activity. Importantly, this allows Y88-phos-
phorylated p27 to be efficiently phosphorylated
on threonine 187 by Cdk2 which in turn pro-
motes its SCF-Skp2-dependent degradation.
This direct link between transforming tyrosine
kinases and p27 may provide an explanation
for Cdk kinase activities observed in p27 com-
plexes and for premature p27 elimination in
cells that have been transformed by activated
tyrosine kinases.
INTRODUCTION
The Cdk-inhibitor p27Kip1 is an intrinsically unstructured
protein (IUP; Lacy et al., 2004) that controls cell
proliferation by binding to and regulating the activity of
cyclin-dependent kinases (Cdks). Usually, binding of
p27 inactivates the kinase; however, p27 was surpris-
ingly also found to be associated with active cyclinD holoenzymes (Sherr and Roberts, 1999). p27 level is
frequently controlled by regulated translation and prote-
olysis (Hengst and Reed, 1996; Pagano et al., 1995).
The protein is abundant in quiescent (G0) cells (Hengst
and Reed, 1998; Sherr and Roberts, 1999) and is rela-
tively stable in G0 and early G1 phase. p27 becomes
unstable as cells progress toward S phase (Hengst and
Reed, 1996; Pagano et al., 1995). p27 degradation is
initiated by different ubiquitin ligases. Among these, the
KPC1 complex ubiquitinates free unphosphorylated p27
(Kamura et al., 2004; Kotoshiba et al., 2005), whereas
Skp2-dependent E3 ligase complexes target p27 only
after phosphorylation on threonine 187 (T187) (Bloom
and Pagano, 2003; Sabile et al., 2006). Active cyclin
E/Cdk2 can phosphorylate T187 of cyclin/Cdk-bound
p27 (Bloom and Pagano, 2003). While free and active
cyclin/Cdk2 efficiently phosphorylates Cdk-bound p27,
p27-bound Cdk2 is catalytically inactive due to p27-
mediated remodeling of the catalytic cleft and displace-
ment of ATP (Pavletich, 1999). This suggested that
degradation by the SCF-Skp2 pathway may require
p27-free cyclin E/Cdk2 and led to the puzzle of how
p27 degradation can be initiated in G1.
We now report that p27 can be phosphorylated
on a tyrosine residue at position 88 (Y88) within its
Cdk-binding domain. This phosphorylation caused the
inhibitory 310-helix of p27 to be ejected from the ATP-
binding pocket of Cdk2. Y88-phosphorylated p27 still
bound to cyclin/Cdk complexes, but the associated
kinase retained significant catalytic activity. Furthermore,
Y88-phosphorylated p27 became an efficient substrate
for phosphorylation on T187 by Cdk2 within the trimeric
complex. Thus, Y88 phosphorylation may trigger p27
ubiquitination in the absence of free cyclin/Cdk2 and
may initiate SCF-Skp2-dependent p27 degradation at
the G1/S transition.Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc. 269
Figure 1. p27Kip1 Binds the Tyrosine
Kinase Lyn and Is Phosphorylated on
Tyrosine
(A) All tyrosine residues (indicated as Y) of p27
are located in the Cdk-inhibitory domain (dark
gray). A proline-rich SH3-binding element (res-
idues 91–96) is represented as a black box.
(B) Lyn binds to a p27 mutant protein lacking all
three tyrosines. p27, a mutant of p27 where the
tyrosines were exchanged to phenylalanine,
and an activated allele of the 56 kDa isoform
of Lyn (Y508F) were expressed in HeLa cells
as indicated. Cells were collected 24 hr post-
transfection, and p27 was immunoprecipitated
(lanes 1–3 and 5–7, anti-p27 polyclonal anti-
body; lane 4, immunoprecipitation with control
IgG). Immunoprecipitates were separated by
SDS-PAGE, and p27-associated Lyn (upper
panel) and precipitated p27 (lower panel)
were detected in western blots. In lane 3,
a SH3 domain-binding-deficient mutant of
p27 (P94G, P95G, K96A; *) was coexpressed
with activated Lyn.
(C) p27 is phosphorylated on tyrosine. 2D
phosphoamino acid analysis of immunoprecip-
itated p27 is shown. HeLa cells transfected
with untagged p27 were labeled with [32P]-
ortho-phosphate. Protein extracts were boiled,
and p27 was immunoprecipitated and sepa-
rated by SDS-PAGE. Autoradiography of im-
munoprecipitated p27 is shown before (left
panel, left lane) and after (right lane) excision of the protein. Excised p27 was hydrolyzed and subjected to 2D cellulose thin-layer electrophoresis.
The autoradiography (middle) shows phosphate incorporation into serine, threonine, and tyrosine. Partially hydrolyzed phosphopeptides are indi-
cated by asterisks. The migration of standards representing phosphoserine, -threonine, or -tyrosine is also shown after ninhydrin staining (right panel).
(D) Lyn and Abl phosphorylate Y88 of p27 in vitro. Equal amounts of p27 or mutant p27 (tyrosine residues exchanged to phenylalanine; Y1F: Y in
position 74 exchanged to F; Y2: Y in position 88; and Y3: Y in position 89) were incubated with recombinant constitutively active Lyn or Abl kinase
at 30C in the presence of g-[32P]-ATP. Proteins were separated by SDS-PAGE and detected by Coomassie staining (upper panel). The amount of
incorporated 32P was shown by autoradiography (lower panel).
(E) p27 is phosphorylated on Y88 in vivo. HA-tagged p27 was coexpressed in 293T cells with Lyn (Y508F) or p210 BCR-ABL kinase. Anti-HA immu-
noprecipitates were incubated with (+) or without calf intestinal alkaline phosphatase (CIAP) and analyzed by western blotting using purified polyclonal
anti-phospho-Y88 p27 antibodies. The same blot was subsequently probed with an HRP-conjugated anti-p27 antibody.
(F) p27 tyrosine phosphorylation is enhanced by overexpression of Lyn or BCR-ABL kinase. MCF7 cells transiently coexpressing either HA-tagged
p27 or mutant HA-tagged p27 (Y88F and Y89F, as indicated) and BCR-ABL or Lyn kinase were treated with sodium orthovanadate for 4 hr. Tagged
p27 species were immunoprecipitated with anti-HA antibodies and analyzed with purified polyclonal anti-phospho-Y88 p27 antibodies. The same
membrane was subsequently probed with an HRP-conjugated anti-p27 antibody.
(G) Monomeric p27 is a better substrate for Abl kinase than p27 bound to a cyclin A/Cdk2 complex. Stable complexes of p27 bound to cyclin A/Cdk2
were isolated by gel filtration chromatography. Equal amounts of monomeric or cyclin A/Cdk2-bound p27 were incubated with or without Abl kinase
as indicated, and proteins were separated by SDS-PAGE and analyzed for Y88 phosphorylation by using a monoclonal pY88-specific antibody.RESULTS
p27 Is Phosphorylated on Tyrosine
While searching for p27-interacting proteins, we affinity
purified Grb2 from HeLa cell extracts. The C-terminal SH3
domain of Grb2 bound to a proline-rich segment of p27 as
shown previously (M.G., unpublished data; Moeller et al.,
2003; Sugiyama et al., 2001). We speculated that addi-
tional SH3 domain proteins might bind p27 and found that
the SH3 domain of the tyrosine kinase Lyn bound to p27.
Within the Cdk-inhibitory domain the p27 sequence
contains three tyrosine residues near the proline-rich
SH3-binding element (Figure 1A). To investigate if phos-
phorylation of tyrosines influenced binding of p27 to the
kinase, we exchanged these tyrosine residues to phenyl-270 Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc.alanine. The binding of p27 to an activated 56 kDa isoform
of Lyn was strongly enhanced when mutant p27 was ex-
pressed (Figure 1B). Without Lyn overexpression, p27
could still coprecipitate endogenous Lyn (Figure 1B), which
may be catalytically inactive and therefore more stably
bound to p27. These observations suggested that p27 is
a substrate of tyrosine kinases.
To investigate tyrosine phosphorylation of p27, we first
performed a phosphoamino acid analysis of immunopre-
cipitated, overexpressed p27 from [32P]-ortho-phosphate-
labeled HeLa cells. While phosphoserine was most
abundant, phosphothreonine and phosphotyrosine were
detected at similar and significant levels (Figures 1C and
S1; Table S2). Recently, tyrosine phosphorylation of p27
was also reported in NB4 promyelocytic leukemia cells
(Kardinal et al., 2006). We next determined that the nonre-
ceptor tyrosine kinases Lyn and Abl could phosphorylate
p27 in vitro (Figure 1D).
To identify the tyrosine residues phosphorylated by Lyn
or Abl, we replaced combinations of one, two, or all three
tyrosine residues of p27 with phenylalanine. Only mutant
proteins that retained Y88 were efficiently phosphorylated
in vitro (Figure 1D). p27 lacking tyrosine 74 and tyrosine 89
was phosphorylated to approximately the same extent
as wild-type (WT) p27. Thus, Y88 is a major phospho-
acceptor site of p27. Lyn did not efficiently phosphorylate
proteins in which Y88 was replaced with phenylalanine,
whereas Abl still phosphorylated proteins that lacked
Y88 but retained Y89, although it did so with reduced
efficiency (Figure 1D). The similarity of the level of phos-
phorylation of WT p27 and of the mutant protein that con-
tained only Y88 indicated that on average only one tyrosine
per inhibitor molecule becomes phosphorylated. Y88 is
therefore a principal phosphoacceptor site of p27 in vitro.
We next investigated whether p27 is also a substrate for
Lyn and Abl kinases in vivo by generating phosphospecific
antisera against phosphotyrosine-containing peptides
(Figures 1E and S2). In the absence of overexpressed ty-
rosine kinases, Y88 phosphorylation was readily detected
in immunoprecipitated p27 of MCF7 cells (Figure 1F),
whereas longer exposures were required to detect Y88
phosphorylation in 293T cells (Figure 1E; data not shown).
When p27 was coexpressed with constitutively active Lyn
(mutant Y508F) or p210 BCR-ABL, the level of phosphor-
ylation was significantly increased (Figures 1E and 1F).
Thus, phosphorylation of Y88 on p27 occurs in vivo and
is enhanced by overexpression of these tyrosine kinases.
Y88 is located in the inhibitory 310-helix of p27 and be-
comes deeply buried within the ATP-binding pocket within
the catalytic cleft of Cdk2 (Pavletich, 1999; Russo et al.,
1996). To determine whether p27 within cyclin/Cdk com-
plexes could still be phosphorylated on Y88, we purified
p27/cyclin A/Cdk2 ternary complexes using two succes-
sive rounds of size-exclusion chromatography (SEC).
Equal amounts of monomeric or cyclin A/Cdk2-bound p27
were incubated with Abl kinase. While monomeric p27 was
a better substrate for Abl phosphorylation, tyrosine phos-
phorylation of cyclin A/Cdk2-bound p27 was clearly de-
tected (Figure 1G). The intrinsic flexibility of p27 (Lacy
et al., 2004) may enable Y88 to fluctuate to an ‘open’ con-
formation that allows phosphorylation by tyrosine kinases.
Y88-Phosphorylated p27 Binds
Cyclin/Cdk Complexes
Phosphorylation of Y88 might prevent binding of p27 to
cyclin/Cdk complexes or induce a different mode of bind-
ing. We used SEC (Figure 2A) and surface plasmon reso-
nance (SPR; Table 1) to characterize interactions between
tyrosine-phosphorylated p27 and Cdk complexes. The re-
sults of SEC showed that both unmodified p27 and Y88-
phosphorylated p27 (pY88-p27) bound to recombinant
cyclin A/Cdk2 (Figure 2A). To exclude phosphorylation of
Y89 in SPR analysis, we used a protein where tyrosine89 was replaced by phenylalanine (p27Y89F). Cdk inhibition
by p27Y89F was indistinguishable from that of WT p27
(data not shown). Cyclin A/Cdk2 bound to immobilized
p27Y89F and pY88-p27Y89F with similar values of the equi-
librium dissociation constant (KD of 4.4 3 10
9 M versus
3.83 109 M, respectively; Table 1; Figure S3). Y88 phos-
phorylation did not influence the binding of isolated cyclin
A to p27Y89F (KD of 49.6 3 10
9 M versus 40.3 3 109 M
for p27Y89F and pY88-p27Y89F, respectively; Table 1; Fig-
ure S5). This interaction may be especially important for
the trimeric complex formation, as p27 bound to cyclin A
in the absence of Cdk2 but did not form a stable complex
with Cdk subunits (Hall et al., 1995). In contrast, isolated
Cdk2 bound to pY88-p27Y89F significantly more weakly
(KD = 4.52 3 10
6 M) than it did to p27Y89F (KD = 248 3
109 M) (Table 1 and Figure S4), suggesting that phos-
phorylation of Y88 weakened the binding of p27 to
Cdk2. Finally, we also demonstrated that Y88-phosphory-
lated p27 still bound to cyclin/Cdk complexes in vivo, as
endogenous Y88-phosphorylated p27 in K562 cells coim-
munoprecipitated in complexes with cyclin D1 and cyclin
E1 (Figure 2B).
pY88-p27-Bound Cyclin/Cdk Complexes Retain
Catalytic Activity
Y88 phosphorylation weakens binding to isolated Cdk2,
which indicates that Y88 phosphorylation alters the p27/
Cdk interaction and inhibition. Indeed, pY88-p27Y89F
was a slightly less potent inhibitor of Cdk2 than unphos-
phorylated p27Y89F (Figures 2C, S7A, and S7B). Impor-
tantly, in contrast to the complete inhibition observed
with p27Y89F, Cdk2 exhibited significant kinase activity
(20% of maximal) even when saturated with pY88-
p27Y89F (Figure 2C). This observation may be biologically
relevant and may provide an explanation for a number of
reports that describe active Cdk2 kinase coimmunopreci-
pitating with p27 (Ciarallo et al., 2002; Radeva et al., 1997).
The retinoblastoma protein (Rb) is recruited as a sub-
strate to cyclin A/Cdk2 through interactions between its
K/RXL motif and an exposed hydrophobic pocket on cy-
clin A (Schulman et al., 1998). As p27 also occupies this
pocket on cyclin A, we investigated Rb phosphorylation
by pY88-p27. With Rb as a Cdk2 substrate Y88 phos-
phorylation also diminished inhibitory potency of p27
(Figure 2D). Phosphorylation of Y88 also impaired the abil-
ity of p27 to inhibit the Rb-kinase activity of a single-chain
cyclin D1/Cdk4-fusion protein (Figure 2E). Therefore, im-
paired Cdk inhibition is a general consequence of p27
Y88 phosphorylation.
pY88 of p27 Is Ejected From the Cdk2 Catalytic Cleft
We used solution NMR spectroscopy to elucidate the
structural consequences of pY88 phosphorylation. We
studied the N-terminal Cdk-inhibitory domain p27-KIDY89F
because the C terminus (residues 105–198) did not influ-
ence Cdk-inhibitory properties of p27 variants (compare
Figures 2C and S7B). While several p27-KID subdomains,
including the 310-helix, are folded prior to bindingCell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc. 271
Figure 2. Y88-Phosphorylated p27 Binds Cdk Complexes
Cdks are partially active even when saturated with Y88 phosphorylated p27.
(A) Tyrosine-phosphorylated and unphosphorylated recombinant p27 were mixed in a ratio of 1:1 and subsequently incubated with cyclin A/Cdk2.
Protein complexes were separated by gel filtration from unbound p27. Fractions were analyzed by Coomassie staining (upper panel) and western
blotting (lower panels) using anti-phosphotyrosine antibodies (pY) reacting with p27 and Abl, a sequence-specific polyclonal pY88-p27 antibody,
and a HRP-coupled anti-p27 antibody as indicated.
(B) pY88-p27 binds cyclin D and cyclin E complexes in vivo. Cyclin D1 and cyclin E1 complexes were immmunoprecipitated from the K562 cell
lysates. Precipitates were analyzed using anti-pY88-p27 and HRP-conjugated anti-p27 antibodies.
(C) Results of cyclin A/Cdk2 kinase-inhibition assays using p27Y89F (triangles) and pY88-p27Y89F (‘‘X’’ symbols) with histone H1 as substrate. The error
bars correspond to ± one standard deviation of the mean based on triplicate measurements.
(D) Rb-kinase of cyclin A/Cdk2 remains partially active in the presence of tyrosine-phosphorylated p27. Equal amounts of tyrosine-phosphorylated
(pY-p27) or mock-treated recombinant p27 (top panel) were incubated with purified cyclin A/Cdk2 and investigated for their ability to inhibit kinase
activity using Rb as a substrate. The incorporation of 32P into Rb is shown. The inhibitory activity of phosphorylated p27 is about 10-fold reduced upon
tyrosine phosphorylation.
(E) As in (D), but a single-chain cyclin D1/Cdk4 kinase was used with pRb as a substrate.cyclin/Cdk complexes, overall the polypeptide is intrinsi-
cally disordered and dynamic (Lacy et al., 2004;
Sivakolundu et al., 2005; Figure S8A). Upon binding to
cyclin A/Cdk2, both p27-KIDY89F and pY88-p27-KIDY89F
adopted a conformation (Figures S8B and S8D) largely
consistent with that of p27-KID bound to cyclin A/Cdk2
in crystals (Russo et al., 1996). Strikingly, however, the
NMR data showed that while locally folded (Figure S9),
residues within the 310-helix of pY88-p27-KID
Y89F did
not interact with Cdk2 (Figures 3B, S8C, and S8D). These
results showed that phosphorylation of Y88 caused the
p27 310-helix to be ejected from the ATP-binding pocket
of Cdk2 (compare Figures 3A and 3B). Importantly, this
local structural disruption did not affect the binding of
other p27 residues to cyclin A/Cdk2. Thus, ejection of272 Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc.the 310-helix from the active site allowed Cdk2 to retain
significant activity when cyclin A/Cdk2 was bound to
pY88-p27Y89F (and to pY88-p27-KIDY89F). The activity of
pY88-bound Cdk2 may be reduced relative to that of
the binary cyclin A/Cdk2 complex because the structure
of the N-terminal, b sheet lobe of Cdk2 is altered by the
binding of p27, domain 2 (Russo et al., 1996).
Y88 Phosphorylation Promotes Cdk2-Mediated
Phosphorylation of p27 at T187
p27 is not only an inhibitor but is also a substrate of
Cdk2. When Cdk2 phosphorylates T187, this modification
promotes p27 degradation by the SCF-Skp2 ubiquitin-
proteasome pathway (Bloom and Pagano, 2003). Binding
to the Cdk complex appears to be important for
Table 1. Surface Plasmon Resonance (SPR) Analysis of p27 Species Binding to Cyclin A, Cdk2, and Cyclin A/Cdk2
Protein Interaction ka (M
1 s1) 3 103 kd (s
1) 3 104 KD (M)
p27Y89F + cyclin A/Cdk2a   4.4 (± 0.1) 3 109
pY88-p27Y89F + cyclin A/Cdk2a   3.8 (± 0.1) 3 109
p27Y88,89F + cyclin A/Cdk2a   5.8 (± 0.1) 3 109
p27Y89F + Cdk2b 1.51 ± 0.01 3.75 ± 0.04 2.48 (± 0.04) 3 107
pY88-p27Y89F + Cdk2b 0.73 ± 0.01 33.03 ± 0.12 4.52 (± 0.08) 3 106
p27Y89F + cyclin Aa   49.6 (± 0.1) 3 109
pY88-p27Y89F + cyclin Aa   40.3 (± 0.1) 3 109
p27-KIDY89F + cyclin A/Cdk2a   2.9 (± 0.1) 3 109
pY88-p27-KIDY89F + cyclin A/Cdk2a   2.7 (± 0.1) 3 109
p27-KIDY89F + Cdk2b 2.31 ± 0.01 4.41 ± 0.05 1.91 (± 0.03) 3 107
pY88-p27-KIDY89F + Cdk2b 1.16 ± 0.01 10.42 ± 0.05 8.98 (± 0.12) 3 107
p27-KIDY89F + cyclin Aa   38.7 (± 0.1) 3 109
pY88-p27-KIDY89F + cyclin Aa   30.3 (± 0.1) 3 109
Equilibrium dissociation constants and kinetic rate constants for unphosphorylated and phosphorylated p27Y89F and p27-KIDY89F
binding to cyclin A/Cdk2, Cdk2, and cyclin A, as well as p27Y88,89F binding to cyclin A/Cdk2 are shown as determined using surface
plasmon resonance (SPR).
a Equilibrium dissociation constants were determined by equilibrium affinity analysis. Biphasic binding was observed by kinetic
analysis; therefore, kinetic rate constants were not determined.
b Equilibrium dissociation constants were calculated from kinetic rate constants as KD = kd / ka, where ka is the association rate
constant, and kd is the dissociation rate constant.phosphorylation of p27, as a mutant of p27 that lacked
stable cyclin/Cdk interaction and that was unable to inhibit
the kinase complex (data not shown) was not efficiently
phosphorylated by Cdk2 (Figure 4A, p27-DCdk).
As Cdk2 was partially active when pY88-p27 was
bound, we determined whether pY88-p27 was a better
substrate for Cdk phosphorylation than unphosphorylated
p27. p27 was first phosphorylated on Y88 with Abl kinase.
Phosphorylated or mock-treated p27 was incubated firstwith cyclin A/Cdk2 and then with [32P] g-ATP, and phos-
phorylation of p27 by Cdk2 was determined. Phosphoryla-
tion of unmodified p27 by Cdk2 was marginal, whereas
pY88-p27 was efficiently and exhaustively phosphorylated
by Cdk2 (Figures 4A and S13). Using phospho-T187-p27-
specific antibodies we confirmed that this increased phos-
phorylation by Cdk2 involved increased phosphorylation
of T187 (Figure 4B). Importantly, enhanced T187 phos-
phorylation was specific for phosphorylation of Y88, asFigure 3. Phosphorylation of p27 Y88
Ejects the 310-Helix from the ATP-Bind-
ing Pocket of Cdk2
NMR chemical shift differences (Dd) between
(A) free p27-KIDY89F and p27-KIDY89F bound
to cyclin A/Cdk2 are compared with those for
(B) free pY88-p27-KIDY89F and pY88-p27-
KIDY89F bound to cyclin A/Cdk2. Dd values
were calculated using the equation: Dd = [(Dd
HN)
2 + 0.0289 3 (Dd NH)
2]1/2. The location of
these domains within the sequence of p27-
KID is indicated at the top of the figure. Amino
acid residues are indicated using the single
letter code.Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc. 273
Figure 4. Y88 Phosphorylation Primes p27 for T187 Phosphorylation
(A) Y88-phosphorylated p27 is a superior substrate for Cdk2. pY88-p27Y89F and p27Y89F were compared to a p27 mutant that is unable to bind cyclin
A/Cdk2 complexes (p27-DCdk) as substrates for cyclin A/Cdk2. Proteins were incubated with recombinant cyclin A/Cdk2 and g-[32P]-ATP. 32P
incorporation into p27 was detected by autoradiography.
(B) Y88 phosphorylation but not Y89 phosphorylation promotes T187 phosphorylation by Cdk2 in vitro. p27, p27Y88F, and p27Y89F were phosphor-
ylated by recombinant Abl-kinase (+) and incubated with cyclin A/Cdk2 at 37C for 5 min. The degree of p27 phosphorylation at T187 was detected by
a phospho-T187-specific antibody. The membrane was subsequently probed with an HRP-conjugated anti-p27 antibody. The tyrosine-phosphory-
lation status of the p27 used in this assay was confirmed in separate western blots utilizing anti-phospho-Y88- or anti-phospho-Y89-specific anti-
bodies.
(C) Y88 phosphorylation of p27 promotes phosphorylation of T187 by enabling a pseudo-unimolecular reaction mechanism. Total p27Y89F/cyclin
A/Cdk2 protein concentration dependence of the rate of phosphorylation of T187 for reactions with p27Y89F and pY88-p27Y89F is shown. The symbols
indicate experimental data points (triangles, p27Y89F; squares, pY88-p27Y89F), and the solid lines illustrate curves calculated using Equation 1 (black
trace for p27Y89F) and Equation 2 (gray trace for pY88-p27Y89F). The error bars correspond to ± one standard deviation of the mean based on triplicate
measurements. See Table S1 and Supplemental Data for details of the curve-fitting procedure.
(D) T187 within a separate polypeptide (p27DN) was phosphorylated to the same extent as T187 within p27Y89F but to a significantly smaller extent than
T187 within pY88-p27Y89F. Experimental conditions were the same as for those illustrated in Figure 4C except that an equimolar amount of p27DN was
also included. The extent of T187 phosphorylation in pY88-p27Y89F and p27DN or p27Y89F and p27DN by Cdk2 was determined in PhosphorImager
scans (see Figure S10). A mutant protein carrying alanine in position of T187 was not phosphorylated in these experiments (data not shown).
(E) Y88 phosphorylation promotes T187 phosphorylation in vivo. 293T cells transiently coexpressing either the HA-tagged WT p27 or a p27-Y88F
mutant and Lyn kinase were treated with Na-orthovanadate and proteasome inhibitor for 4 hr. HA-tagged p27 was immunoprecipitated with an
anti-HA antibody. Immunoprecipitates were analyzed with a phospho-T187-specific antibody. The membrane was subsequently probed with an
HRP-conjugated anti-p27 antibody.a protein phosphorylated on Y89 was not a good substrate
for Cdk2-dependent phosphorylation (Figure 4B). Thus,
Y88 phosphorylation primes p27 for subsequent T187
phosphorylation.
We hypothesized that Cdk2-mediated phosphorylation
of pY88-p27 on T187 occurred via a pseudo-unimolecular
mechanism within the same ternary pY88-p27/cyclin
A/Cdk2 complex. To test this model, we determined the274 Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc.ternary complex concentration dependence of this reac-
tion rate. At all concentrations, significant phosphorylation
of pY88-p27Y89F was observed (Figure 4C), while p27Y89F
was phosphorylated to a much smaller extent. Similar
experiments were performed in the presence of a compet-
ing C-terminal fragment of p27 (residues 105–198; p27DN),
which fails to bind to the kinase complex. With
the Y88-phosphorylated complex, pY88-p27Y89F was
phosphorylated on T187 to a much greater extent than
p27DN, while with the Y88-unphosphorylated complex,
p27Y89F and p27DN were phosphorylated to similar but
much smaller extents (Figures 4D and S10). Mathematical
analysis of the reaction rates (Figure 4C) revealed that
phosphorylation of Y88 primes p27 for Cdk2-mediated
phosphorylation of T187 by allowing the reaction to
proceed via an unprecedented pseudo-unimolecular
mechanism (shown in the Supplemental Data). Y88 phos-
phorylation thus promotes a transition of p27 from an
inhibitor into a substrate of Cdk2.
Tyrosine Phosphorylation Primes for T187
Phosphorylation In Vivo
To investigate if phosphorylation of p27 on Y88 promoted
subsequent Cdk2-mediated phosphorylation at T187
in vivo, we coexpressed constitutively active Lyn with
p27 in 293T cells. Expression of Lyn strongly enhanced
T187 phosphorylation of p27 in comparison to the untrans-
formed control (Figure 4E). To eliminate the possibility that
enhanced T187 phosphorylation was an indirect result of
Lyn overexpression that was independent of Y88 phos-
phorylation, we expressed a mutant p27 protein in which
Y88 was replaced by phenylalanine. Consistent with our
model of the specific importance of pY88 in priming phos-
phorylation of T187, this mutant exhibited significantly
reduced T187 phosphorylation (Figure 4E).
Imatinib Inhibits Y88 Phosphorylation
of p27 by BCR-ABL
The BCR-ABL oncogene is a product of the Philadelphia
translocation which causes chronic myelogenous leuke-
mia (CML) and BCR-ABL-positive acute lymphoblastic
leukemia (ALL). The constitutively active kinase induces
and maintains leukemic transformation (Huettner et al.,
2000). BCR-ABL is specifically inhibited by Imatinib mesy-
late/STI571/Gleevec (Wong and Witte, 2004). To deter-
mine if tyrosine phosphorylation of p27 directly depended
on BCR-ABL kinase activity, we added STI571 to 293T
cells transfected with BCR-ABL and p27. Y88 phosphory-
lation was barely detectable 2 hr after addition of STI571,
which confirms that Y88 phosphorylation required active
BCR-ABL (Figure 5A). Addition of STI571 to Lyn-trans-
fected cells did not affect Y88 phosphorylation by Lyn
(Figure 5A), which indicates that STI571 is specific for
BCR-ABL and supports the hypothesis that p27 might
be a specific substrate of BCR-ABL.
We next investigated Y88 phosphorylation of p27 in a
BCR-ABL-transformed tumor cell line, K562. These CML
cells express a p210 BCR-ABL kinase that is inhibited by
STI571.Endogenousp27 ofK562cells was phosphorylated
on Y88 (Figure5B). Addition of STI571 abrogated Y88 phos-
phorylation (Figure 5B), suggesting that tyrosine phosphor-
ylation of p27 depended on sustained BCR-ABL tyrosine
kinase activity. In comparison to 293T cells, Y88 phosphor-
ylation of endogenous p27 declined more slowly in STI571-
treated K562 cells (compare Figures 5A, 5B, and S11). This
suggests that additional tyrosine kinases that have beenactivated by BCR-ABL may contribute to p27 tyrosine
phosphorylation. Among other tyrosine kinases, Lyn is
induced by p210 BCR-ABL in hematopoietic cells
Figure 5. Inhibition of BCR-ABL reduces p27-Y88 Phosphor-
ylation and BCR-ABL Inhibition, and Y88F Mutation Stabilizes
the p27 Protein
(A) Imatinib/STI571 prevents BCR-ABL-induced p27 tyrosine phos-
phorylation. 293T cells were transfected with HA-tagged p27 and
BCR-ABL or Lyn kinase and then treated with 10 mM STI571 for the
times indicated. Equal amounts of cell lysates were analyzed by west-
ern blotting with monoclonal anti-pY88-p27 antibodies and HRP-con-
jugated anti-p27 antibodies as indicated.
(B) STI571 prevents tyrosine phosphorylation of endogenous p27 in
K562 cells. K562 cells were treated with 10 mM STI571 for 2 and 4
hr. p27 level and Y88 phosphorylation were determined by western
blotting of p27 immunoprecipitates using monoclonal anti-pY88-p27
and HRP-conjugated anti-p27 antibodies.
(C) STI571 increases p27 levels in K562 cells. Cells were treated with 2
or 10 mM STI571 for 16 hr, and equal amounts of protein were analyzed
by western blotting utilizing anti-p27 and anti-PSTAIRE antibodies.
(D) STI571 increases the stability of p27 in K562 cells. K562 cells were
mock-treated or treated with 10 mM STI571 for 16 hr. Cells were labeled
with [35S]-methionine and [35S]-cysteine for 1 hr and subsequently in-
cubated in the absence of radioactive amino acids for the times indi-
cated. p27 was immunoprecipitated using polyclonal anti-p27 anti-
bodies. The radioactive protein was visualized by autoradiography.
The intensity of the bands was determined using a PhosphorImager
and is expressed as a fraction of the time point 0. Triplicate experi-
ments gave similar results; representative results are shown.
(E) p27Y88F is more stable than p27. Subconfluent cultures of p27/
MEFs were retrovirally transduced with p27 or p27Y88F and labeled
with a [35S] methionine/cysteine mix for 1.5 hr. p27 was immunoprecip-
itated and visualized by autoradiography. One representative of three
independent experiments is shown.Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc. 275
(Danhauser-Riedl et al., 1996). Activated Lyn and BCR-
ABL may both contribute to Y88 phosphorylation of p27.
BCR-ABL Activity Destabilizes p27
Phosphorylation of p27 on T187 can initiate its Skp2-
dependent ubiquitination and degradation (Bloom and
Pagano, 2003). Therefore, increased T187 phosphoryla-
tion stemming from Y88 phosphorylation may explain
the enhanced degradation of p27 in tumors harboring ac-
tivated tyrosine kinases. Consistent with this hypothesis,
the level of p27 protein was dramatically increased follow-
ing STI571 treatment (Figure 5C) as described previously
in BCR-ABL-transformed cells (Coutts et al., 2000; Ges-
bert et al., 2000; Jonuleit et al., 2000). The increase in
p27 protein upon inhibition of BCR-ABL kinase by STI571
correlated with an increase in endogenous p27 stability as
demonstrated in pulse-chase experiments (Figure 5D),
which further supports the hypothesis that tyrosine phos-
phorylation primes for p27 degradation.
Mutation of Tyrosine 88 to Phenylalanine
Stabilizes p27
p27 stabilization upon BCR-ABL inactivation might be
a consequence of cell-cycle arrest in G1 phase. To more
directly investigate the role of Y88 phosphorylation in
p27 stability, we retrovirally expressed p27 or a p27-
Y88F mutant in immortalized p27/ mouse embryonic fi-
broblasts (MEFs). p27 that can be phosphorylated on Y88
showed a half-life comparable to that described for en-
dogenous p27 (123 min ± 20.5 min; Figure 5E). By con-
trast, the p27-Y88F mutant was significantly more stable
(half-life of 204 min ± 21.1 min; Figure 5E). It is unlikely
that stabilization of p27 results from an inability of the mu-
tant to bind to Cdk2 complexes because we determined
that p27Y89F and p27Y88,89F have similar affinities for cyclin
A/Cdk2 (Figure S6 and Table 1).
p27Y88F Exhibited Enhanced Cdk-Inhibitory
Potency In Vivo
Because pY88-p27 exhibited reduced Cdk-inhibitory ac-
tivity and stability, we speculated that a mutant protein
that could not be phosphorylated would be more potent
in arresting BCR-ABL-transformed tumor cells. We there-
fore expressed p27 and p27Y88F in K562 cells. Conditions
were adjusted to express WT and mutant p27 at similar
levels (Figure 6A, right panel). Ectopic expression of p27
at a high level led to accumulation of cells in G1 phase ir-
respective of the mutation of Y88F (data not shown). How-
ever, expression at an intermediate level revealed that p27
failed to arrest K562 cells in G1 phase, whereas expres-
sion of the mutant p27Y88F at this level resulted in an in-
creased number of G1 phase cells and a reduced number
of S phase cells, respectively (Figure 6A).
Y88 of p27 Is Phosphorylated in G1 Phase
Elevated Y88 phosphorylation might be a hallmark of can-
cer cells and/or a regulatory mechanism that mediates
progression of normal cells through the division cycle.276 Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc.Figure 6. Tyrosine 88 Phosphorylation of p27 Is Increased in
Serum-Stimulated and G1 Phase Cells
(A) p27Y88F is more potent than p27 in arresting K562 cells. K562 cells
were electroporated with p27- or p27Y88F-expressing vectors and
a GFP-expressing vector. Expression levels of p27 are shown in the
right panel. Forty-eight hours following transfection, GFP-expressing
cells were isolated by cell sorting and labeled with BrdU for 3 hr. The
DNA content was determined by flow cytometry after staining for
DNA with propidium-iodide and for replicated DNA using anti-BrdU
FITC-labeled antibodies. A representative experiment is shown.
(B) p27 is tyrosine phosphorylated in G1 phase. Extracts of proliferating
or arrested HeLa cells were analyzed for p27 Y88 phosphorylation. Ty-
rosine-phosphorylated p27 was immunoprecipitated using a monoclo-
nal pY88-p27-specific antibody and was detected by western blotting
using a polyclonal pY88-specific antibody. Extracts used for immuno-
precipitations were analyzed by western blotting with p27- and a-tubu-
lin-specific antibodies as indicated. Using the same protein extracts in
a second blot, expression of Skp2, pT187-p27, p27, and actin were
determined for cells arrested in lovastatin, thymidine, and nocodazole
as shown in the right panel.
(C) Serum stimulation enhances Y88 phosphorylation. RPMI-8226
cells were starved for 24 hr in medium containing 0.2% FCS. Starved
cells were stimulated with 20% FCS and 10 ng/ml IL6 for 30 min. Thirty
minutes prior to stimulation all cells were treated with 1 mM Na-ortho-
vanadate. Y88-phosphorylated p27 was precipitated using mono-
clonal anti-pY88-p27-specific antibodies and detected by western
blotting using a p27-specific HRP-conjugated antibody. Lyn was
immunoprecipitated, and active Lyn was detected with a phospho-
Y396-specific antibody. p27, actin, and Lyn expression were analyzed
in total cell extracts.
To investigate whether Y88 phosphorylation also regu-
lated endogenous p27 at specific points of the cell cycle,
we determined the extent of Y88 phosphorylation for p27
in HeLa cells. pY88-p27 was detected in proliferating
HeLa cells (Figure 6B), and its levels were increased
when cells were arrested in G1 phase using lovastatin.
Lovastatin-arrested cells did not express Skp2 and accu-
mulated p27 phosphorylated on both Y88 and T187
(Figure 6B). By contrast, Y88 phosphorylation was re-
duced in cells arrested using thymidine and nocodazole
in S or G2/M phase, respectively (Figure 6B).
We also observed increased Y88 phosphorylation after
stimulation of starved RPMI-8226 myeloma cells with
serum and IL-6 (Figure 6C). IL-6 is a potent growth factor
for plasmocytoma/myeloma cells (Kawano et al., 1988)
that leads to activation of Lyn kinase (Hallek et al., 1997).
Serum starvation reduced Lyn activity, and stimulation
increased Lyn activity (Figure 6C). In parallel, serum star-
vation reduced Y88 phosphorylation, and growth-factor
stimulation led to an increase in p27-Y88 phosphorylation.
This is consistent with a possible contribution of specific
Src-family tyrosine kinases to p27 Y88 phosphorylation.
DISCUSSION
A number of links between p27 and multiple oncogenic
pathways have been established and include the Ras,
Myc, and Akt/PKB pathways (Blain et al., 2003). We add
here a direct link between p27 inactivation and tyrosine
kinase activation. Whereas a single unmodified Cip/Kip
protein is sufficient for Cdk2 inhibition (Hengst et al.,
1998; Russo et al., 1996), phosphorylation of Y88 in p27
impaired its ability to inhibit the bound kinase complex,
and, even in the presence of a large excess of pY88-
p27, inhibitor-bound kinases retained substantial catalytic
activity. This mechanism may explain previous observa-
tions of active kinase complexes coimmunoprecipitating
with p27 (Blain et al., 1997; Cheng et al., 1999; Dong
et al., 1998; LaBaer et al., 1997; Soos et al., 1996).
In addition, Y88 phosphorylation triggered Cdk2-medi-
ated threonine 187 phosphorylation through a pseudo-
unimolecular mechanism and initiated proteolysis of the
Cdk inhibitor. This suggests that p27 Y88 phosphorylation
may be one mechanism to initiate SCF-Skp2-dependent
p27 degradation during the normal cell cycle. Further,
this mechanism may contribute to tumor formation that
involves activated tyrosine kinases. For example, p27
may be deregulated by constitutive Y88 phosphorylation
in BCR-ABL-positive leukemias. While overexpressed
BCR-ABL directly phosphorylates p27, BCR-ABL-acti-
vated tyrosine kinases are likely to contribute to p27 Y88
phosphorylation. One such kinase that is activated by
BCR-ABL is Lyn, a tyrosine kinase that directly binds
p27. In addition, we demonstrate that c-src coprecipitates
with p27 (Chu et al., 2007 [this issue of Cell]). Src phos-
phorylates the tyrosine residues 88 and 74 of p27. In ac-
cordance with our observation reported here, phosphory-
lation by Src also leads to reduced stability of p27 andimpaired Cdk inhibition by p27. Interestingly, Src activa-
tion correlates with low nuclear p27 in primary human
breast cancers, further indicating the link between
oncogenic tyrosine kinases and p27 (Chu et al., 2007
[this issue of Cell]).
The intrinsic flexibility of p27 (Lacy et al., 2004; Sivako-
lundu et al., 2005) enables the two-step phosphorylation
cascade that triggers p27 degradation. First, intrinsic flex-
ibility allows the Y88-phosphorylated 310-helix to rotate
out of the Cdk2 active-site cleft without weakening other
interactions with cyclin A/Cdk2. This Y88 phosphoryla-
tion-induced structural change transforms p27 from a
Cdk inhibitor into a captive Cdk substrate. Second, exten-
sive flexibility within the p27 C terminus enables T187 to
encounter the Cdk2 active site within the same pY88-
p27/cyclin A/Cdk2 ternary complex.
Consistent with our model, p27 levels are decreased in
CML-CD34+ cells as compared to normal CD34+ cells
(Andreu et al., 2005). Treatment with STI571 restored
p27 levels. Interestingly, STI571 treatment of BCR-ABL-
positive leukemia patients frequently leads to relapse due
to drug-resistant clones. STI571-resistant tumor cell lines
have been characterized by elevated Lyn expression
(Donato et al., 2003). While STI571 inhibits Y88 phosphor-
ylation by BCR-ABL, it fails to do so in Lyn-expressing
cells (Figure 5A).
While potentially important in oncogenesis by activated
tyrosine kinases, the pattern of Y88 phosphorylation
during the cell cycle suggests that Y88 phosphorylation
regulates p27 activity and stability in normal cells. As
Y88 is conserved in all Cip/Kip family inhibitors, it will be
interesting to determine whether this residue is also phos-
phorylated in p21 or p57. As tyrosine phosphorylation
relieves Cdk inhibition by p27, this may explain observa-
tions of a number of groups that active Cdk complexes
can coprecipitate with p21 and p27, hence enabling the
inhibitors to act as assembly factors and, thus, activators
of Cdks (Cheng et al., 1999; Sherr and Roberts, 1999).
EXPERIMENTAL PROCEDURES
Cell Culture
K562 and RPMI-8226 cells were maintained in RPMI 1640; HeLa,
293T, MCF7, and p27/ MEFs were maintained in DMEM. Media
were supplemented with 10% FBS, 1 mM pyruvate, 50 U/ml penicillin,
and 100 mg/ml streptomycin. RPMI-8226 cells were serum starved for
24 hr in medium containing 0.2% FBS. Cell synchronization and cell-
cycle analysis with BrdU and PI was performed as described (Hengst
and Reed, 1996).
Phosphoamino Acid Analysis
HeLa cells expressing untagged p27 were metabolically labeled with
0.5 mCi [32P]-ortho-phosphate for 4 hr. Cells were lysed, p27 immuno-
precipitated with a C-terminal antibody (C-19, Santa Cruz Biotechnol-
ogy), separated by SDS-PAGE, and blotted on PVDF membrane.
Phosphorylated p27 was excised from the membrane and hydrolyzed
in 6N HCl. Resulting free amino acids were mixed with phosphoamino
acid standard (Sigma) and fractionated by 2D thin-layer chromatogra-
phy (pH 1.9 and pH 3.5) as described (Boyle et al., 1991). Phosphory-
lated amino acids were analyzed by overlaying autoradiogram of TLCCell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc. 277
plate with the position of amino acid standard on the same plate and
were visualized by ninhydrin staining.
Antibodies
Polyclonal antibodies specific for Y88-phosphorylated p27 were gen-
erated by immunizing rabbits with the ovalbumin-coupled peptide
LPEF-phosphoYYRPPR. Antisera were purified by passage on a col-
umn linked to the unphosphorylated peptide followed by purification
on a column linked to the phosphorylated peptide. Antibodies against
Y89-phosphorylated p27 were generated using the coupled peptide
PEFYphospho-YRPPRP, and antibodies against Y88-Y89-phosphory-
lated p27 were generated using the peptide LPEFphospho-Yphospho-
YRPPR. Monoclonal antibodies directed against Y88-phosphorylated
p27 were generated using the peptide in mice. p27-pT187-specific an-
tibodies from Zymed or from Upstate were preadsorbed with soluble
recombinant p27 and were subsequently tested for crossreactivity
with the unphosphorylated protein. p27 was detected and precipitated
using a polyclonal antibody (C-19, Santa Cruz Biotechnology). Active
Lyn was detected with a phospho-Y396-specific rabbit monoclonal
antibody (Epitomics) after immunoprecipitation with a mouse mono-
clonal Lyn antibody (BD).
Pulse–Chase Analysis
K562 cells (1 3 107/ml) were cysteine/methionine starved for 45 min
and incubated with 50 mCi/ml [35S] cysteine/methionine (ProMix,
Amersham) for 1 hr. Following washes, cells were incubated in
isotope-free media supplemented with 0.1 mg/ml cysteine and
0.1 mg/ml methionine then analyzed as described (Hengst and
Reed, 1996). p27/ MEFs stably expressing Lyn (Y508F) were retro-
virally transduced with p27 or a p27-Y88F mutant. Cells were starved
for 45 min, labeled with a [35S] cysteine/methionine for 1.5 hr, and
analyzed as described above.
Protein Expression and Analysis; Kinase and Phosphatase
Reactions
p27 cDNAs were expressed in E. coli. Human Cdk2 and full-length cy-
clin A were purified from baculovirus-infected Sf9 cells. In kinase reac-
tions, p27 was added to cyclin A/Cdk2. To determine IC50 at elevated
p27 level, 1.5 ng/ml and 0.3 ng/ml kinase were used. A baculovirus
encoding cyclin D1 and Cdk4 as a single polypeptide linked by a poly-
alanine sequence was expressed in Sf9 cells. The SH3 and kinase
domains of murine Abl were amplified by PCR, subcloned into
pET28a-vector, expressed, and purified from E. coli. Human Lyn was
purchased from Sigma and Upstate.
Tyrosine phosphorylation by Abl or Lyn kinases was performed for
up to several hours at 37C in a buffer containing 20 mM HEPES
(pH 7.5), 250 mM NaCl, 5 mM MgCl2, 1 mM MnCl2, 0.05% NP40,
7.15 mM b-mercaptoethanol, 125 mM Na-orthovanadate, protease in-
hibitors, and 1 mM ATP. Radioactive kinase reactions were performed
at 30C for 45–90 min with 10 mCi g-[32P]-ATP and 25 mM cold ATP. For
subsequent reactions, Y-phosphorylated p27 was repurified by includ-
ing a step of heat denaturation (100C; 10 min.) to inactivate the tyro-
sine kinase. Activity of recombinant cyclin/Cdk complexes was deter-
mined as described (Hengst et al., 1998). Gel filtration analysis was
performed on a Sephadex 200 HR column in 150 mM NaCl, 50 mM
Tris (pH 7.5), 1 mM PMSF, and 1 mM DTT. Fractions (0.5 ml) were col-
lected at a flow rate of 0.6 ml/min at 4C by isocratic elution over 1.5
column volumes. Fractions were analyzed using SDS-PAGE with Coo-
massie or western blot detection.
Protein Expression and Purification for SPR, NMR,
and In Vitro Kinase Assays
cDNA for residues 22–104 (p27-KID), 105–198 (p27DN), and 1–198 (full-
length) of human p27 were subcloned into pET28a (Novagen). Similar
constructs were prepared with Y89 mutated to F. These proteins, hu-
man Cdk2, T160-phosphorylated Cdk2, and truncated human cyclin A
(residues 173–432 of human cyclin A) were expressed in E. coli and278 Cell 128, 269–280, January 26, 2007 ª2007 Elsevier Inc.purified as described (Lacy et al., 2004). Y88-phosphorylated p27-
KIDY89F and p27Y89F were prepared by incubating Abl kinase domain
and the p27 samples at 30C for 2 hr followed by Fe3+-affinity chroma-
tography. Isotope-labeled samples of p27-KID and p27 were prepared
as described (Neidhardt et al., 1974) using 15N-ammonium chloride,
13C-glucose, and 2H2O. To produce p27-KID labeled at specific amino
acids with 15N, an auxotrophic E. coli strain DL39(DE3) was cultured in
MOPS-based minimal media supplemented with amino acids (Waugh,
1996).
SPR Experiments
Kinetic studies were performed using a BIACORE 3000 (Biacore, Inc.)
SPR instrument. p27 polypeptides were immobilized as previously re-
ported (Lacy et al., 2004) and as given under Supplemental Data. The
kinetics of association and dissociation to immobilized p27 species
were monitored using 20–2000 nM Cdk2, 3.9–250 nM cyclin A, and
0.4–40 nM cyclin A/Cdk2 complex. Data from triplicate injections for
each analyte were analyzed by simultaneously fitting association
phases and dissociation phases at all concentrations using the pro-
gram CLAMP (Myszka and Morton, 1998) with a 1:1 binding model.
The association rate constants and dissociation rate constants (ka
and kd, respectively) for Cdk2 binding to p27 constructs were used
to calculate the corresponding equilibrium dissociation constants
(KD) using KD = kd / ka. The binding of cyclin A and cyclin A/Cdk2 to
the p27 species exhibited biphasic kinetics; therefore, binding iso-
therms were generated from the response at equilibrium for each
injection, and KD values were determined using the program Scrubber
(Version 1.1g, BioLogic Software).
NMR Spectroscopy
p27 polypeptides and their complexes with cyclin A/Cdk2 were ana-
lyzed using NMR spectroscopy at 800 MHz using methods described
previously (Wang et al., 2005) and as reported under Supplemental
Data.
In Vitro Cdk2 Kinase Activity Assays and Kinetic Studies
of T187 Phosphorylation
The inhibitory profiles of p27 and pY88-p27 species were determined
by measuring in vitro Cdk2 kinase activity toward histone H1 in the
presence of different concentrations of p27-KIDY89F, p27Y89F, and their
Y88-phosphorylated analogs. The experimental details are given un-
der Supplemental Data. Kinetic analysis of the T187-phosphorylation
reaction mechanisms was performed with five different concentrations
(0.25, 0.5, 1.0, 2.0, and 4.0 mM) of p27Y89F/cyclin A/Cdk2 and
pY88-p27Y89F/cyclin A/Cdk2. These reagents were equilibrated with
g-[32P]-ATP for four time intervals (20, 40, 60, and 120 min) and were
followed by analysis using SDS-PAGE. In addition, similar reactions
were performed for 40 min in the presence of equimolar concentra-
tions (with respect to ternary complex constituents) of p27DN.
Supplemental Data
Supplemental Data include equations, Supplemental Experimental
Procedures, 13 figures, and two tables and can be found with this
article online at http://www.cell.com/cgi/content/full/128/2/269/DC1/.
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